The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and mitigate supply chain vulnerabilities, including collaborating with the private sector to develop and implement programs to assess and incentivize resiliency in manufacturer and hospital purchasing behavior. The paper focuses on generic sterile injectable medicines used in inpatient settings, citing their importance and relative risk of supply disruptions.

Related News Articles

Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response June 5 announced it selected two locations to test an…
Headline
The U.S. Court of International Trade May 28 blocked a series of tariffs issued by the Trump administration under the International Emergency Economic Powers…
Chairperson's File
Public
We are all closely watching changing tariff policy as it raises serious considerations for the medical products, devices and pharmaceuticals supply chain. Our…
Chairperson's File
Public
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…
Headline
The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In…